Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pneumonia I: Introduction

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...

Pneumonia I: Introduction

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...

Atypical Pneumonia

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...

Pneumonia III: Complications and Assessment

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:

Pneumonia II: Pathophysiology

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:

Pneumonia V: Nursing management and Prevention

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Clinical characteristics of diffuse idiopathic pulmonary neuroendocrine cell hyperplasia.

ERJ open research·2026

Same author

Characteristics and predictors of clinical outcome in patients with pleural effusions caused by heart, liver and renal failure: results from the ERS International Multicentre Pleural Research Collaborative (IMPACT) registry.

ERJ open research·2025

Same author

Structured narrative review on lung cancer screening: current evidence, clinical practice implications and implementation insights from a multidisciplinary task force and patient representatives.

European respiratory review : an official journal of the European Respiratory Society·2025

Same author

Clinical and Sleep Characteristics and the Effect of CPAP Treatment on Obese Patients with Obstructive Sleep Apnea and Asthma-A Retrospective Study.

Healthcare (Basel, Switzerland)·2025

Same author

Benefits from <sup>18</sup>F-FDG PET-CT-Based Radiotherapy Planning in Stage III Non-Small-Cell Lung Cancer: A Prospective Single-Center Study.

Cancers·2025

Same author

Complete Blood Cell Count Parameters Predict Mortality in Patients with Hypersensitivity Pneumonitis.

Diagnostics (Basel, Switzerland)·2025

Search research articles

Related Experiment Video

Updated: Jun 16, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Community acquired bacterial pneumonia.

Stavros Anevlavis¹, Demosthenes Bouros

¹Department of Pneumonology, University Hospital of Alexandroupolis, Democritus University of Thrace, Medical School, Alexandroupolis 68100, Greece.

Expert Opinion on Pharmacotherapy

|January 21, 2010

Summary

This summary is machine-generated.

Community-acquired pneumonia (CAP) management is improving with new prognostic tools and therapies. Further research is needed to optimize patient outcomes for this leading infectious cause of death.

Related Experiment Videos

Last Updated: Jun 16, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Area of Science:

Infectious Diseases
Pulmonology
Critical Care Medicine

Background:

Community-acquired pneumonia (CAP) is a significant global health challenge, being the leading cause of death from infectious diseases worldwide.
CAP imposes a substantial economic burden on healthcare systems globally.
Despite its prevalence, effective management strategies are continuously evolving.

Purpose of the Study:

To review current evidence on prognostic scoring systems and biomarkers for assessing CAP severity.
To summarize recent advances in therapeutic approaches for CAP, including novel antibiotic and nonantibiotic strategies.
To provide an overview of the evolving landscape of CAP management.

Main Methods:

Systematic literature search of PubMed for English-language articles published between 1997 and 2009.
Keywords included 'community acquired pneumonia', 'therapy', 'antibiotics', 'prognostic scoring systems', and 'biomarkers'.
Review focused on evidence related to diagnostic tools, prognostic indicators, and therapeutic interventions.

Main Results:

The review details recent therapeutic advancements and novel approaches in managing CAP.
Current evidence on the utility of prognostic scoring systems and biomarkers in CAP patient management is summarized.
The effectiveness and ongoing debate surrounding empirical antimicrobial regimens are discussed.

Conclusions:

Recent developments have significantly advanced the clinical management of CAP.
However, several critical areas require further investigation through prospective studies.
Optimizing patient outcomes for CAP necessitates continued research into unresolved therapeutic and diagnostic questions.